Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression

IntroductionA prior retrospective analysis demonstrated that quantifying Programmed Cell Death Ligand 1 (PD-L1) expression using a phosphor-integrated dot (PID) score effectively predicted immune checkpoint inhibitor (ICI) efficacy in non-small-cell lung cancer (NSCLC) and other cancers. However, PD...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Takashi Shimizu, Ryotaro Ohkuma, Mayumi Homma, Shingo Nakayama, Yosuke Sasaki, Satoshi Muto, Katsuaki Ieguchi, Makoto Watanabe, Akashi Taguchi, Daisuke Takayanagi, Youichiro Wada, Atsushi Horiike, Yutaro Kubota, Hirotsugu Ariizumi, Masahiro Shimokawa, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Emiko Mura, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Hiroyuki Suzuki, Toshiko Yamochi
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2025-09-01
سلاسل:	Frontiers in Immunology
الموضوعات:	tumor Akkermansia muciniphila immunohistochemistry PD-L1 immunecheckpoint inhibitors biomarker
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1528594/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!